Brand profile · Biotechnology Research

BCAL Diagnostics

BCAL Diagnostics is a Biotechnology Research brand in Sydney, New South Wales. Publicly held, at bcaldiagnostics.com. It holds one address on record, all in Australia. It employs 20 people, on the record. One Australian registration (ABN) is a candidate match. Its latest round on record is Post IPO equity, US$10.5M. It is listed alongside eight similar brands, mostly in Biotechnology Research.

Profile live Public Company Founded 2010 1 registry match ABN 1 office country US$ 10.5M Post IPO equity
Registry match · ABR

Key facts

Counted staff
20
self-reported 11–50 band
Founded
2010
16 years
Registry matches
1
ABR
Office countries
1
1 address
Funding rounds
1
Post IPO equity · Jul 2024 · US$ 10.5M
Company type
Public Company
self-reported
Use this profile Compare Your shortlist

Legal entity

1 brand → 1 possible registrationThe join is a normalised name comparison against ABR. Treat every row below as a lead to verify, not as an established identity.
  • BCAL DIAGNOSTICS LIMITED

    ABN51142051223

    NSWMedium confidenceMatched on exact nameABR

Legal entities

BCAL Diagnostics: 1 registry entityBCAL Diagnostics is linked to 1 registry entity: BCAL DIAGNOSTICS LIMITED (ABN 51142051223, candidate).BCAL DiagnosticsBCAL DIAGNOSTICSLIMITEDABN 51142051223Candidate · Medium confidence
Show as table · BCAL Diagnostics: 1 registry entity
BCAL Diagnostics: 1 registry entity
BCAL DIAGNOSTICS LIMITEDABN 51142051223
Confirmed matches0 of 1

A candidate is a name match on the registry, not a confirmed identity, and two candidates are ambiguity rather than a corporate structure.

Description

BCAL Diagnostics is an Australian-owned, ASX listed, biotechnology company. Since its establishment in 2010, BCAL Diagnostics has been striving to help identify health issues in women that is safe, accessible and cost effective.

Locations

Country footprint

Offices in 1 countryCountry footprint: 1 country. Codes: AU.1 countryAU
Show as table · Offices in 1 country
Offices in 1 country
Countries1

All codes: AU

Addresses

  • AUSuite 506 Level 5 50 Clarence Street Sydney NSW 2000; Sydney, New South Wales 2000

Grid intelligence Members

Funding

Last round · 3 July 2024US$ 10.5MPost IPO equity
Rounds1
Round typePost IPO equity · secondary transaction
Amount (USD)10,500,000
Stage rank6
Investors named0
Since last round1 yr 6 mo

Funding

1 funding roundFunding timeline. Latest round 3 Jul 2024: Post IPO equity, US$ 10.5M.20102026Post IPO equityUS$ 10.5M1 round
Show as table · 1 funding round
1 funding round
Rounds1
Axis2010 to 2026
Post IPO equity · 3 Jul 2024US$ 10.5M

Dated rounds only. The axis ends at the date this profile was last observed, not at today.

Spending power

TheGrid Corporate Spending Power index would rate purchasing capacity from registry, scale and activity signals.

Spending power

Signals & hiring

Hiring, headcount and registry-change signals, streamed to members.

Latest signal
Hiring activity
Headcount trend

Financials

Registry-filed capital and financial indicators, standardised by TheGrid.

Paid-up capital
Fiscal period
Registered charges
Revenue
Profit / loss

People & contacts

4 employee profiles on record · names withheld.

Names and titles are intentionally absent from this page. The source relation carries no consent record across the privacy regimes this directory spans, so it is never requested and never stored. Search engines see exactly what you see here.

The people relation is never requested, so there is nothing here to unlock.

Notify me about contacts Tell us who you need to reach and we will tell you when a consented source is live.

FAQ

Which legal entity operates under BCAL Diagnostics?

One New South Wales entity on the ABR: BCAL DIAGNOSTICS LIMITED (ABN 51 142 051 223), medium confidence.

How many people work at BCAL Diagnostics?

20 counted staff profiles at January 2026, inside the self-reported 11–50 band.

Where does BCAL Diagnostics have offices?

One address on record, Australia only.

Has BCAL Diagnostics raised funding?

One round. Latest 3 July 2024: post IPO equity, US$10,500,000.

Which companies are listed alongside BCAL Diagnostics?

15 profiles list BCAL Diagnostics as a peer — 90th percentile in Biotechnology Research. It lists ten peers of its own. Island Pharmaceuticals and Sydney Breast Clinic list it back.

What is BCAL Diagnostics's website?